BioSpace News Archive

Maze Therapeutics today announced new data from an exploratory muscle biopsy cohort of its Phase 1 clinical trial of MZE001 in healthy volunteers to evaluate the effects of MZE001 on glycogen synthesis.

FSD Pharma Inc. today announced that its Australian entity, FSD Pharma Australia Pty Ltd. received the certificate of approval from The Alfred Ethics Committee in Australia to proceed with a Phase 1 study.

Andira Pharmaceuticals announces it will carry out pharmacologic characterization of its lead compounds for metastatic breast cancer through a collaborative research program with the University of British Columbia (UBC), Vancouver.

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) today announced it has entered a research agreement with Georgetown University focused on the evaluation of the Company’s lead HDAC6 inhibitor candidate, SP-2-225, evaluating the anti-tumor effect of the combination of SP-2-225 and RT in a syngeneic breast cancer model.

Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced the first patient dosed of their first-in-human, phase 1/2 study, GaLuCi™.

Marengo Therapeutics, Inc., a company pioneering novel immuno-therapeutics targeting the T cell receptor (TCR) Vβ repertoire to fight cancer and other diseases, today announced that the company will present a late-breaking abstract at the upcoming American Association for Cancer Research (AACR) Annual Meeting, held April 14-19 in Orlando, Florida.

AbCellera (Nasdaq: ABCL) and RQ Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio, including influenza and cytomegalovirus (CMV).

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2023 results on Wednesday, May 3, 2023 at 1 p.m. London time (8 a.m. Eastern Time).

HAGAR announced today promising preliminary data from its clinical study with Professor Ami Navon from the Weizmann Institute of Science for its non invasive glucose monitoring device, GWave.

Applied DNA Sciences, Inc. announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC, has submitted a validation package to the New York State Department of Health in support of approval for a pharmacogenomics assay as a NYSDOH laboratory-developed test.